Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor
Kavya Ramkumar(The University of Texas MD Anderson Cancer Center), Nouri Neamati(Michigan Medicine)
Cited by 74
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Current Challenges and Opportunities in Treating Glioblastoma
|Pharmacological Reviews|2018|888
Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
|Nature Communications|2023|84
Mechanisms underlying the cytotoxicity of a novel quinazolinedione‐based redox modulator, <scp>QD</scp>232, in pancreatic cancer cells
|British Journal of Pharmacology|2014|9